Kevin J. Carroll - Publications

Efficacy of diflunisal for hereditary transthyretin amyloidosis: the Swedish real-world experience.

Journal: Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis

Published: June 03, 2026

Rejoinder to Commentaries on "A Perspective on the Appropriate Implementation of ICH E9(R1) Addendum Strategies for Handling Intercurrent Events".

Journal: Statistics in medicine

Published: May 07, 2026

Sibeprenlimab in IgA Nephropathy - Interim Analysis of a Phase 3 Trial.

Journal: The New England journal of medicine

Published: November 10, 2025

Early Change in Proteinuria as a Surrogate Endpoint in Studies of IgA Nephropathy: An Updated Patient-Level Meta-analysis and Discussion of Appropriate Methodology.

Journal: Advances in therapy

Published: September 03, 2025

Evaluating Sibeprenlimab in IgA Nephropathy - Rationale and Baseline Data from the VISIONARY Trial.

Journal: Kidney international reports

Published: June 06, 2025

Camlipixant in Refractory Chronic Cough: A Phase 2a, Randomized Controlled Trial (RELIEF).

Journal: American journal of respiratory and critical care medicine

Published: March 05, 2025

Camlipixant in Refractory Chronic Cough: A Phase 2b, Randomized, Placebo-controlled Trial (SOOTHE).

Journal: American journal of respiratory and critical care medicine

Published: March 05, 2025

A Perspective on the Appropriate Implementation of ICH E9(R1) Addendum Strategies for Handling Intercurrent Events.

Journal: Statistics in medicine

Published: July 02, 2024

Inhaled colistimethate sodium in patients with bronchiectasis and Pseudomonas aeruginosa infection: results of PROMIS-I and PROMIS-II, two randomised, double-blind, placebo-controlled phase 3 trials assessing safety and efficacy over 12 months.

Journal: The Lancet. Respiratory medicine

Published: April 18, 2024

Hexasodium fytate for the treatment of calciphylaxis: a randomised, double-blind, phase 3, placebo-controlled trial with an open-label extension.

Journal: EClinicalMedicine

Published: April 05, 2024

Targeting APRIL in the Treatment of IgA Nephropathy.

Journal: Clinical journal of the American Society of Nephrology : CJASN

Published: October 06, 2023

Daprodustat and Heart Failure in CKD.

Journal: Journal of the American Society of Nephrology : JASN

Published: October 05, 2023